Acelyrin
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 130
- Market Cap
- $503M
- Website
- http://www.acelyrin.com
- Introduction
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Clinical Trials
20
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Hidradenitis Suppurativa Study of Izokibep
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- ACELYRIN Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT05905783
- Locations
- 🇪🇸
Clinical Research Site, Madrid, Spain
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- ACELYRIN Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05683496
- Locations
- 🇦🇺
Clinical Research Site, Nedlands, Western Australia, Australia
Psoriatic Arthritis Study of Izokibep
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- ACELYRIN Inc.
- Target Recruit Count
- 351
- Registration Number
- NCT05623345
- Locations
- 🇪🇸
Clinical Research Site, Sevilla, Spain
🇭🇺Clinical Research Site (003), Budapest, Hungary
Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ACELYRIN Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT05384249
- Locations
- 🇪🇸
Clinical Research Site, Zaragoza, Spain
🇪🇸Clinical Research Site (4007), Santiago De Compostela, Spain
🇪🇸Clinical Research Site (4008), Santiago De Compostela, Spain
Hidradenitis Suppurativa Phase 2b Pivotal Study of Izokibep
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Placebo to izokibep
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- ACELYRIN Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT05355805
- Locations
- 🇪🇸
Clinical Research Site, Barcelona, Spain
- Prev
- 1
- 2
- Next
News
Tang Capital's Concentra Biosciences Acquires Elevation Oncology for $0.36 Per Share in Latest Biotech Liquidation
Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights.
Third Harmonic Bio Stockholders Approve Liquidation Plan as THB335 Shows 85% Tryptase Reduction in Phase 1 Trial
Third Harmonic Bio stockholders overwhelmingly approved a liquidation and dissolution plan with 99.9% of voting shares supporting the proposal at the June 5, 2025 annual meeting.
Alumis and Acelyrin Announce Merger Deal, Suspend Phase III Plans for Lonigutamab
• Alumis and Acelyrin have entered into a merger agreement, marking a significant consolidation in the biotechnology sector. • The companies announced the suspension of the planned Phase III program for lonigutamab following disappointing Phase II results reported in January. • The merger decision includes a strategic reassessment of lonigutamab's development program to evaluate its potential value and future direction.
Alumis and Acelyrin Announce Merger to Create $737M Clinical-Stage Biopharma Company
Alumis and Acelyrin have agreed to merge in an all-stock transaction, creating a combined entity with $737 million in cash runway extending into 2027.
Acelyrin's Lonigutamab Shows Promise in Thyroid Eye Disease with Optimized Dosing Strategy
• Acelyrin's lonigutamab Phase 1/2 study update reveals that lower doses administered every four weeks were subtherapeutic for thyroid eye disease (TED). • The company's analysis determined that a minimum concentration of 3 ug/ml is required for maximized efficacy, achievable with a 100 mg loading dose followed by 50 mg every two weeks. • Phase 3 program for lonigutamab in TED is set to begin in the first quarter of 2025, utilizing the optimized dosing regimen based on pharmacokinetic data. • H.C. Wainwright adjusted Acelyrin's stock target to $6.00, maintaining a Neutral rating, reflecting the Phase 1/2 study findings and future trial design.
Acelyrin's Lonigutamab Shows Promise in Phase 2 Data for Thyroid Eye Disease
• Acelyrin's lonigutamab demonstrates a potential best-in-class efficacy and safety profile for treating Thyroid Eye Disease (TED), according to updated Phase 2 data. • A virtual investor event on January 6, 2025, will feature clinician perspectives on unmet needs in TED and the design of the Phase 3 LONGITUDE program. • The Phase 3 LONGITUDE program, developed after discussions with the FDA, aims to be the most inclusive registrational program in TED to date. • Lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, offers potential for longer-term, convenient dosing, improving clinical response.
Acelyrin's Lonigutamab Shows Promise in Thyroid Eye Disease Phase 2 Data
• Acelyrin will present Phase 2 data for subcutaneous Lonigutamab, indicating a potentially best-in-class efficacy and safety profile for Thyroid Eye Disease (TED). • The company plans to unveil the design for its Phase 3 program following a successful meeting with the FDA. • A virtual investor event is scheduled to reveal the data and Phase 3 design, featuring experts from Stanford and the University of Colorado School of Medicine.
Acelyrin Inc. Faces Market Volatility Amidst Clinical Trial Updates
Acelyrin Inc. (SLRN) stock reached a 52-week low amidst challenging market conditions, reflecting broader economic pressures and investor concerns.
Acelyrin's Izo Fails Phase 2b/3 Trial in Uveitis; Wells Fargo Adjusts Price Target
• Acelyrin's Phase 2b/3 trial of izokibep (izo) in uveitis has failed, leading to the removal of its contribution from Wells Fargo's financial model. • Wells Fargo has lowered its price target for Acelyrin from $15 to $13, while maintaining an Overweight rating on the shares. • The firm believes the downside impact on Acelyrin's stock will be limited due to the market not assigning significant value to the uveitis program.
Acelyrin's Izokibep Advances in Phase 3 Trials Amidst Analyst Revisions and Institutional Investment
• Acelyrin's lead drug candidate, Izokibep, is currently in Phase 3 clinical trials for Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, and Phase 2 trials for Axial Spondyloarthritis. • Institutional investors, including Point72 Asset Management L.P., have increased their positions in Acelyrin, indicating confidence in the company's potential. • Several analysts have adjusted their price targets for Acelyrin, reflecting evolving expectations for the company's performance and the potential of Izokibep. • Acelyrin's stock experienced trading fluctuations, highlighting the dynamic nature of the biopharmaceutical market and investor sentiment towards the company.